




## **Product Details**

Product name:	Anti-human LIV-1 / SLC39A6 (Ladiratuzumab vedotin Biosimilar	) SKU:	BIO0865SM
Target Name:	LIV-1 / SLC39A6	Size:	1 mg/5 mg/20 mg
Target Uniprot:	Q13433	Concentration:	Lyophilized
Clone#:	Ladiratuzumab vedotin	Isotype:	Human IgG1
Reactivity:	Human	Calculated M.W.:	146.96 kDa
Application:	ELISA, Bioactivity: FACS, Functional assay, Research in vivo	Endotoxin:	<0.001 EU/ug
Formulation:	0.1M Pro, 20mM Arg, pH5.0	Conjugation:	MMAE(ADC)
Storage:	For long term storage, the produce should be stored at -20° C or lower.	Expression System:	СНО
Reconstitution:	Dissolve with sterile ddH2O	Purification:	Protein A


### Data

## **Purity:SDS-PAGE**




Anti-LIV-1 / SLC39A6 ((ladiratuzumab vedotin) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 95%.

# **Purity:SEC-HPLC**




The purity of Anti-LIV-1 / SLC39A6 ((ladiratuzumab vedotin) is 98.2%, determined by SEC-HPLC.

## **Bioactivity: ELISA**



Immobilized human LIV 1, His Tag at 2 ug/mL can bind Anti-LIV-1 / SLC39A6 ((ladiratuzumab vedotin),EC50=0.007652 ug/mL.

## **Bioactivity:FACS**



Human LIV1 CHOS cells were stained with Anti-LIV-1 / SLC39A6 (ladiratuzumab vedotin) and negative control protein respectively, washed and then followed by PE and analyzed with FACS, EC50=0.07456 ug/mL.